Response Biomedical names Jeffrey Purvin as CEO
Response Biomedical (TSX:RBM) has named Jeffrey Purvin as CEO, effective yesterday.
Mr. Purvin has over 30 years of experience marketing both consumer and medical products. Most recently, he was chairman and CEO of Calibra Medical, where he and his team developed and gained FDA clearance for a unique insulin delivery device, successfully positioning the company for an exit.
“We are delighted that Jeff has agreed to become our next CEO,” Dr. Peter Thompson, executive chairman and interim CEO, said in a statement. “Jeff’s background and experience are perfectly suited to help drive Response during this very exciting time for the company.”